Back to Trades
Sell4
Maze Therapeutics, Inc.
MAZE
Total Value
$488.3K
Net $332.0K sold
Sales
$332.0K
3 transactions
Company Information
- Company Name
- Maze Therapeutics, Inc.
- Ticker Symbol
- MAZE
- CIK
- 0001842295
Insider Information
- Name
- Dandekar Atul
- Role
- Insider
- Location
- SOUTH SAN FRANCISCO, CA
Filing Details
- Filing Date
- Feb 2, 2026
- Transaction Date
- Jan 29, 2026
- Accession Number
- 0002050167-26-000003
- Form Type
- 4
- Net Trading Amount
- -$332.0K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jan 29, 2026 | Common Stock | 7,500 | $10.42 | Exercise | $78.2K |
| Jan 29, 2026 | Common Stock | 1,200 | $43.18 | Sale | $51.8K |
| Jan 29, 2026 | Common Stock | 3,500 | $44.04 | Sale | $154.1K |
| Jan 29, 2026 | Common Stock | 2,800 | $45.01 | Sale | $126.0K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jan 29, 2026 | Derivative | 7,500 | $10.42 | Exercise | $78.2K |
Footnotes
- (F1)This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- (F2)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
- (F3)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive.
- (F4)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive.
- (F5)The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.